Microarray technology has broad applications in cancer research such as identification of cancer markers and gene expression profiling for diagnosis, treatment, and prognosis. Maintenance of a Core DNA Microarray Facility in a comprehensive cancer research center is critical for the success of a growing number of investigators with peer-reviewed funding. The Microarray Facility was established in 1999 using institutional and developmental funds from the CCSG. The Facility provides both printed cDNA and oligo arrays, for investigators to perform gene expression analysis, and full microarray services from RNA sample labeling to array scanning, for those investigators who do not have the capacity to perform microarray experiments in their own laboratories. The Facility also helps investigators to design and print custom microarrays to meet their specific research goals. The Facility is used by 20 investigators, all with peer-reviewed funding, from 9 research Programs in all three Divisions of Fox Chase Cancer Center (FCCC). The microarray usage has increased more than 200% from the year 2002 to 2003 and reached 1,300 microarrays per year. With an increasing number of research grants involving microarray analysis awarded recently, and the establishment of a Laser Capture Microdissection Facility at the Center, combined with RNA amplification procedure which enables small clinical cancer samples to be applied to microarray analysis, we anticipate a 100%-200% increase over the next five years. The microarray products of the Facility include human 40k cDNA and 30k oligo arrays, mouse 15k cDNA and 32k oligo arrays, and 6k yeast oligo arrays. A rat oligo library will be acquired to meet the needs of those investigators using rat models to study breast and ovarian oncogenesis. The Facility has also designed and produced customer design specific arrays, such as DNA repair process-related gene arrays. Standard microarray procedures and optimized labeling and hybridization kits, as well as a Microarray Training Program, have been made available to microarray users. A comprehensive microarray quality control procedure has been implemented to ensure the quality of microarray products and services. The Facility coordinates with the Bioinformatics Facility for microarray data analysis and management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-44
Application #
7310517
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
44
Fiscal Year
2006
Total Cost
$121,761
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :

Showing the most recent 10 out of 1280 publications